Drugs / LUSVERTIKIMAB
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT03980080 | Dec 2018 → Nov 2019 | — | OSE Immunotherapeutics | Completed | No outcome recorded |
| Phase 21 trial · 1 met primary | ||||||
| Phase 2 | NCT04882007 | Oct 2020 → Apr 2024 | ulcerative colitis | OSE Immunotherapeutics | Completed | Met primary |
Evidence & citations 6 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | LUSVERTIKIMAB | ChEMBL registry synonym — accepted as the source's own label CHEMBL4650498 ↗ |
| Known as | OSE-127 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04882007 ↗ |
| Action | Inhibit | “mAb antagonist to CD127 receptor (or IL-7Rα)” NCT03980080 ↗ |
| Modality | Monoclonal antibody | “mAb antagonist to CD127 receptor (or IL-7Rα)” NCT03980080 ↗ |
| Route | Intravenous | “Single (IV and SC)” NCT03980080 ↗ |
| Route | Subcutaneous | “Single (IV and SC)” NCT03980080 ↗ |